scale up pitfalls [Study Per­for­mance]

posted by Dr_Dan  – 2016-10-26 17:11  – Posting: # 16754
Views: 1,673

Dear all
Provided that a lab scale batch of a generic formulation demonstrated bioequivalence to the RLD how big would be the risk of commercial scale batch to fail?
IMHO factors affecting the formulation after method transfer to the CMO are different manufacturing equipment and different total amounts of drug and excipients. If the formulation and the manufacturing process remains the same and all characteristics and specification of critical quality attributes of the drug product, such as dissolution are met wouldn't it be reasonable to assume bioequivalence for the commercial scale batch? Do you have any experience with failed upscaling?
CPMP/EWP/QWP/1401/98 Rev. 1/ Corr ** states for oral solid forms for systemic action that "the test product should usually originate from a batch of at least 1/10 of production scale or 100,000 units, whichever is greater, unless otherwise justified." Considering this upscaling shouldn´t really be a problem, right?
Looking forward to your reply

Kind regards and have a nice day
Dr_Dan

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,983 posts in 4,228 threads, 1,373 registered users;
online 8 (0 registered, 8 guests [including 4 identified bots]).
Forum time (Europe/Vienna): 15:42 CET

I believe that a scientist looking at nonscientific problems
is just as dumb as the next guy.    Richard Feynman

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5